Status:
UNKNOWN
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Lead Sponsor:
University Hospital, Bonn
Conditions:
DLBCL
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma. Known side effects include ...
Detailed Description
Genetically modified chimeric antigen receptor (CAR) T cells specifically targeting CD19 or "B cell maturation antigen" (BCMA) have shown remarkable advances in the treatment of highly refractory and ...
Eligibility Criteria
Inclusion
- Patients undergoing CAR T-cell therapy
- Consent to participate in study
Exclusion
- Inability to undergo MRI examinations due to large metallic implants, cardiac pacemakers/neurostimulators, or claustrophobia
- Known cardiac conditions such as status post heart attack or myocarditis, complex congenital heard disease, or cardiomyopathies.
- Birth control using an IUD.
- Pregnancy or breastfeeding.
- Renal insufficiency with a GFR below 30 ml/min/1.73m2
Key Trial Info
Start Date :
May 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05414162
Start Date
May 16 2022
End Date
December 1 2025
Last Update
June 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Bonn
Bonn, North Rhine-Westphalia, Germany, 53127